Results of the FDA pivotal clinical trial for the LightTouch Non-invasive Cervical Cancer Detection Device conducted by Guided Therapeutics, Inc. (GT), indicated that the current system for diagnosing cervical disease missed the same amount of disease as a landmark study carried out by the National Cancer Institute (NCI). In the new LightTouch study, 32% of cervical precancers and cancers were missed by the current method of human papillomavirus (HPV) testing and colposcopy.

China Medical Technologies, Inc. has announced that the Company has received approval for its Leukemia BCR/ABL fusion gene detection FISH Probe (the “Leukemia BCR/ABL FISH Probe”) from the State Food and Drug Administration of China (the “SFDA”). The Leukemia BCR/ABL FISH Probe is a molecular diagnostic test kit that uses DNA probes for accurate detection of Philadelphia translocation, which is a specific chromosomal abnormality associated with chronic myelogenous leukemia.

The journal Proceedings of the National Academy of Sciences published a study that examined mice that were given the breast cancer drugs fulvestrant and raloxifene, both of which work by preventing estrogen from functioning in cells, HealthDay News reports. The mice where genetically engineered to carry HPV, an STD strongly linked with cervical cancer. The drugs cleared precancerous growths in the cervix and prevented cancer in mice with precancerous lesions, according to the research.

Scientists from Trinity College Dublin (TCD) have discovered a new drug that can destroy cancerous cells in adult leukaemia patients who have developed resistance to other treatments. During the study, PBOX-15 was found to attack and break down the skeleton in leukaemia cells in samples given by patients. It was also found to effectively treat Chronic Lymphocytic Leukaemia (CLL), which is the most common leukaemia in the western world in adults.